TB-PRACTECAL, a clinical trial led by Médecins Sans Frontières (MSF), has found that a new, all-oral, six-month treatment regimen is safer and more effective at treating rifampicin-resistant tuberculosis (RR-TB) than the current accepted standard of care. These results signal the start of a new chapter for people with drug-resistant (DR)-TB, who currently face lengthy treatment regimens. Read Here.
top of page
Recent Posts
See AllA recent study on the incidence of MDR-TB in children and teens revealed that the prevalence has resurged. there was a 10 year drop from...
The Stop TB Partnership announced a major price reduction on bedaquiline. The cost per treatment course was slashed by over 50%,...
The shutdown and dismantling of USAID has had large ramifications for TB services. As one of the largest funding sources for TB, the...
bottom of page
Komentarze